{
    "nct_id": "NCT03262103",
    "official_title": "Phase I Study of In Situ Autologous Vaccination Against Prostate Cancer With Intratumoral and Systemic Hiltonol® (Poly-ICLC) Prior To Radical Prostatectomy",
    "inclusion_criteria": "* Written informed consent and HIPAA authorization for release of personal health information.\n* Age > 18 years at the time of consent.\n* ECOG Performance Status of 0-1 within 14 days prior to being registered for protocol therapy (Study Procedure Manual).\n* Histologically confirmed adenocarcinoma of the prostate (with previous diagnostic tissue available for tumor marker analysis).\n* Gleason 7 - 10, cT2a - cT3b adenocarcinoma of the prostate with plans for radical prostatectomy\n* PSA ≥ 4 ng/ml\n* Tumor visible on multiparametric MRI\n* Tolerated previous transrectal ultrasound guided biopsy procedure under local anesthetic\n* Uncomplicated previous TRUS biopsy procedure (i.e., no prior hospitalization due to sepsis, prostatic abscess or severe hemorrhage following TRUS prostate biopsy)\n* Willing to undergo the intra-tumoral (IT) injection of the Poly-ICLC into the prostatic tumor as per the protocol\n* No prior hormonal therapy with the exception of oral 5-alpha-reductase inhibitors (finasteride, dutasteride, etc.). Patients who have received prior oral anti-androgen therapies (bicalutamide, flutamide, nilutamide, etc.) must be off treatment for at least 6 weeks prior to enrollment. Patients who have received prior LHRH agonist or antagonist therapy (leuprolide, goserelin acetate, etc.) are eligible provided serum testosterone is > 50 mg/dl.\n* No prior radiation therapy (external beam or brachytherapy) to the pelvis or prostate.\n* No clinically significant infections as judged by the treating investigator.\n* No characteristics suggesting a potential higher risk of infection with intraprostatic injections:\n\n  * Recurrent urinary tract infections or history of prostatitis within 3 months prior to enrollment into the study.\n  * Urine analysis positive for nitrites and leucocyte esterase. Such patients could be considered for the study after treatment and resolution of the infection.\n  * Active proctitis\n  * History of prostatic abscess\n  * Taking immunosuppressive medication including systemic corticosteroids\n  * Active hematologic malignancy\n* No uncontrolled angina, congestive heart failure or MI within 6 months.\n* Patients with history of HIV (if CD4+ T cell counts are ≥350 cells/µL on established ART therapy), Hepatitis B (with viral load below limits of quantification) or Hepatitis C (who have completed a curative therapy and have a viral load below the limit of quantification) are eligible for this study.\n* No treatment with any investigational agent for any medical condition within 28 days prior to being registered for protocol therapy.\n\n  * Adequate end organ function as determined by the following laboratory values:\n\n    * White blood cell count (WBC) > 2.5 k/mm3\n    * Absolute neutrophil count (ANC) > 1.5 k/mm3\n    * Hemoglobin (Hgb) > 8.0 g/dL\n    * Platelets > 100 k/mm3\n    * Calculated creatinine clearance of > 60 cc/min using the Cockcroft-Gault formula:\n\nMales: (140 - Age in years) × Actual Body Weight in kg 72 × Serum Creatinine (mg/dL)\n\n* Bilirubin < 2.0 x ULN\n* Aspartate aminotransferase (AST) < 2.5 x ULN\n* Alanine aminotransferase (ALT) < 2.5 x ULN 18) Able to speak, read and write in English.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}